BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1478 related articles for article (PubMed ID: 23146082)

  • 21. Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy.
    Wiesner C; Pfitzenmaier J; Faldum A; Gillitzer R; Melchior SW; Thüroff JW
    BJU Int; 2005 Feb; 95(3):301-5. PubMed ID: 15679782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy.
    Gupta A; Lotan Y; Bastian PJ; Palapattu GS; Karakiewicz PI; Raj GV; Schoenberg MP; Lerner SP; Sagalowsky AI; Shariat SF;
    Urology; 2008 Feb; 71(2):302-7. PubMed ID: 18308108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy.
    Sonpavde G; Khan MM; Svatek RS; Lee R; Novara G; Tilki D; Lerner SP; Amiel GE; Skinner E; Karakiewicz PI; Bastian PJ; Kassouf W; Fritsche HM; Izawa JI; Ficarra V; Dinney CP; Lotan Y; Fradet Y; Shariat SF
    BJU Int; 2011 Sep; 108(5):687-92. PubMed ID: 21087453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
    Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
    J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy.
    May M; Herrmann E; Bolenz C; Brookman-May S; Tiemann A; Moritz R; Fritsche HM; Burger M; Trojan L; Michel MS; Wülfing C; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Wieland WF; Gilfrich C; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Bastian PJ
    Ann Surg Oncol; 2011 Jul; 18(7):2018-25. PubMed ID: 21246405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
    Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
    J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
    Tilki D; Reich O; Svatek RS; Karakiewicz PI; Kassouf W; Novara G; Ficarra V; Chade DC; Fritsche HM; Gerwens N; Izawa JI; Lerner SP; Schoenberg M; Stief CG; Skinner E; Lotan Y; Sagalowsky AI; Shariat SF
    J Urol; 2010 May; 183(5):1757-63. PubMed ID: 20299059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.
    Isbarn H; Karakiewicz PI; Shariat SF; Capitanio U; Palapattu GS; Sagalowsky AI; Lotan Y; Schoenberg MP; Amiel GE; Lerner SP; Sonpavde G
    J Urol; 2009 Aug; 182(2):459-65; discussion 465. PubMed ID: 19524971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients.
    Rehme C; Fritsch B; Thomas L; Istin S; Burchert C; Hummel B; Baleanu-Curaj B; Reis H; Szarvas T; Ruebben H; Hadaschik B; Niedworok C
    Int Urol Nephrol; 2022 Jan; 54(1):71-79. PubMed ID: 34817753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does patient age affect survival after radical cystectomy?
    Horovitz D; Turker P; Bostrom PJ; Mirtti T; Nurmi M; Kuk C; Kulkarni G; Fleshner NE; Finelli A; Jewett MA; Zlotta AR
    BJU Int; 2012 Dec; 110(11 Pt B):E486-93. PubMed ID: 22551360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple adverse histological features increase the odds of under staging T1 bladder cancer.
    Weizer AZ; Wasco MJ; Wang R; Daignault S; Lee CT; Shah RB
    J Urol; 2009 Jul; 182(1):59-65; discussion 65. PubMed ID: 19447443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].
    Denzinger S; Burger M; Fritsche HM; Ganzer R; Blana A; Wieland WF; Otto W
    Aktuelle Urol; 2008 Jan; 39(1):58-61; discussion 62-3. PubMed ID: 18228189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time between first and second transurethral resection of bladder tumors in patients with high-grade T1 tumors: is it a risk factor for residual tumor detection?
    Süer E; Özcan C; Baltacı S; Gülpınar Ö; Burgu B; Haliloğlu A; Bedük Y
    Urol Int; 2013; 91(2):182-6. PubMed ID: 23751593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.
    Rink M; Lee DJ; Kent M; Xylinas E; Fritsche HM; Babjuk M; Brisuda A; Hansen J; Green DA; Aziz A; Cha EK; Novara G; Chun FK; Lotan Y; Bastian PJ; Tilki D; Gontero P; Pycha A; Baniel J; Mano R; Ficarra V; Trinh QD; Tagawa ST; Karakiewicz PI; Scherr DS; Sjoberg DD; Shariat SF;
    BJU Int; 2013 Mar; 111(3 Pt B):E30-6. PubMed ID: 22938654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy?
    Minardi D; Milanese G; Parri G; Lacetera V; Muzzonigro G
    Arch Ital Urol Androl; 2016 Mar; 88(1):13-6. PubMed ID: 27072170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 74.